GUIDELINES FOR THE TREATMENT OF ANXIETY IN PRIMARY CARE

This guidance has been developed by Barnsley CCG Medicines Management Team in collaboration with colleagues from South West Yorkshire Partnership NHS Foundation Trust (SWYPFT).

The guidance has been subject to consultation and endorsement by the Area Prescribing Committee on 11th December 2013 and the LMC on 14th January 2014.

Contact for advice: Medicines Management Team 01226 433798

Purpose

This guidance has been developed to support a consistent approach to the prescribing of medication for the treatment of Generalised Anxiety Disorder (GAD) and Panic Disorder in primary care. It recommends the approach to the prescribing of medication for adults in routine practice. It does not encompass the approach to patients with complex treatment-refractory GAD, patients with very marked functional impairment or those at high risk of self-harm. Treatment of such patients requires specialist input and often involvement of multi-agency teams.

GENERALIZED ANXIETY DISORDER (GAD)

NICE recommends a stepped approach to treatment of GAD.

1. Identification - All known and suspected presentations of GAD:
   - Identify and communicate the diagnosis of GAD to the patient to help them understand the disorder and start effective treatment promptly.
   - Consider the diagnosis of GAD in people presenting with anxiety or significant worry, and in people who attend primary care frequently who have a chronic physical health problem; do not have a physical health problem but are seeking reassurance about somatic symptoms; are repeatedly worrying about a wide range of different issues.

2. Low-intensity psychological interventions for GAD - If GAD has not improved after education and active monitoring in step 1 interventions – offer one or more of the following as first line options (guided by patient preference):
   - Individual non-facilitated self-help (written or electronic self-help materials)
   - Individual guided self-help
   - Psychoeducational groups

3. Treatment options - GAD with marked functional impairment or that has not improved with steps 1 and 2 above offer:
   - Either individual high intensity psychological interventions (Cognitive behavioural therapy (CBT), applied relaxation)
   - or drug treatment.
There is no evidence that either mode of treatment is better. Provide written information on benefits and disadvantages of either mode to allow the patient to make a choice.

4. Consider referral if the patient with GAD has severe anxiety with marked functional impairment in conjunction with:

   o a risk of self-harm or suicide or
   o significant comorbidity, such as substance misuse, personality disorder or complex physical health problems or
   o self-neglect or
   o an inadequate response to step 3 interventions

For further information on psychological treatments refer to NICE guidelines\textsuperscript{1,2}, the local Psychological Services Department or the local IAPT services on 01226 707600.

**PANIC DISORDER**

NICE also recommends a stepped approach to treatment of panic disorder.

1. Recognition and diagnosis - be alert to the common clinical situation of comorbidity, in particular, panic disorder with depression and panic disorder with substance misuse.

2. Treatment in primary care - psychological therapy, medication and self-help have all been shown to be effective. Treatment choice will be guided by the assessment process and shared decision-making with the patient.

   The interventions that have evidence for the longest duration of effect, in descending order, are:

   o psychological therapy - Cognitive behavioural therapy (CBT)
   o pharmacological therapy (antidepressant medication).
   o self-help - Bibliotherapy based on CBT principles, information about support groups.

   Benefits of exercise as part of good general health should be discussed.

3. Review and consideration of an alternative intervention.

4. Review and referral to specialist mental health services. If there have been two interventions provided (any combination of psychological intervention, medication, or bibliotherapy) and the patient still has significant symptoms, then referral to specialist mental health services should be offered.

The choice of treatment for both GAD and panic disorder should be shared between the patient and clinician. This will improve concordance and clinical outcomes.

**PHARMACOLOGICAL TREATMENT OF GAD AND PANIC DISORDER\textsuperscript{1,3}**

For further information please consult individual drug SPCs in the Medicines Compendium at [www.medicines.org.uk](http://www.medicines.org.uk) or information in the British National Formulary at [www.bnf.org](http://www.bnf.org).

Before prescribing any medication, discuss the treatment options and any concerns the patient has about taking medication. Explain fully the reasons for prescribing and provide written and verbal information on:

Issue Date: December 2013                    Review Date: December 2015
Version 1.0
• the likely benefits of different treatments
• the different propensities of each drug for side effects, withdrawal syndromes and drug interactions
• the risk of activation with SSRIs and SNRIs, with symptoms such as increased anxiety, agitation and problems sleeping
• the gradual development, over 1 week or more, of the full anxiolytic effect
• the importance of taking medication as prescribed and the need to continue treatment after remission to avoid relapse
• Refer to http://www.southwestyorkshire.nhs.uk/service-users-and-carers/help-and-advice/medicines-management/information for patient information resources. Another useful resource for patients is the following website: www.choiceandmedication.org/swyp/

PHARMACOLOGICAL TREATMENT OF GAD (see Algorithm Appendix 1)

Aims of treatment in GAD are to reduce symptoms of anxiety and to minimise disruption to day to day functioning, with minimal adverse effects.

• If a patient with GAD chooses drug treatment, offer a selective serotonin reuptake inhibitor. Sertraline, although unlicensed is recommended as the first line SSRI in NICE guidance because it is the most cost effective.
• If sertraline is ineffective in the treatment of GAD, offer an alternative SSRI such as citalopram or fluoxetine (both unlicensed for treatment of GAD) or offer a SNRI.
• Escitalopram is licensed for the treatment of GAD but has an increased cost without clear benefit over other SSRIs in terms of efficacy.
• Choice should take into account previous experience with the drug, tendency to produce withdrawal syndrome, side effect profile, drug interactions, risk of suicide and likelihood of toxicity in overdose. If the second line option is ineffective or the patient cannot tolerate SSRIs or SNRIs, consider referral to secondary care.
• When prescribing venlafaxine, the first line formulation is standard release tablets. If a once daily or a modified release preparation is required, the most cost-effective option is MR tablets - prescribed generically.
• Combinations of antidepressants or augmentation of antidepressants with other drugs should be initiated by secondary care specialists.
• Pregabalin is classified as an amber drug for the treatment of GAD. When prescribed under shared care arrangements consider prescribing it twice a day rather than three times daily. It is equally as effective but costs are lower.
• In GAD benzodiazepines should be used with caution in the short term and not normally for longer than two to four weeks.
• Do not offer an antipsychotic for GAD in primary care.
PHARMACOLOGICAL TREATMENT OF PANIC DISORDER (see Algorithm Appendix 2)

Aims of treatment in panic disorder are to reduce the severity and frequency of panic attacks, phobic avoidance and anticipatory anxiety and to improve social and occupational functioning, with minimal adverse effects.

- Antidepressants should be the only pharmacological intervention used in the longer term management of panic disorder.
- The two classes of antidepressants that have an evidence base for effectiveness in the treatment of panic disorder are:
  - the selective serotonin reuptake inhibitors (SSRIs).
  - tricyclic antidepressants (TCAs) – clomipramine or imipramine initiated under specialist supervision.
- Unless otherwise indicated, an SSRI licensed for panic disorder should be offered.
  - Citalopram licensed.
  - Paroxetine licensed but not recommended due to increased reporting of discontinuation symptoms and movement disorders.
  - Sertraline licensed.
  - Fluoxetine not licensed, low acquisition costs.
  - Escitalopram licensed but has an increased cost without a clear benefit over other SSRIs in terms of efficacy.
- If an SSRI is not suitable or there is no improvement after a 12-week course consider referral to secondary care.
- Benzodiazepines should not be prescribed for the treatment of panic disorder as in the longer term outcomes are poorer.
- Sedating antihistamines or antipsychotics should not be prescribed for the treatment of panic disorder.
General Advice when Prescribing Antidepressants¹,³

- Doses of SSRIs and SNRIs should be started low and increased gradually to reduce the risks of initial exacerbation of anxiety symptoms.
- SSRIs and SNRIs may take up to 3 months to produce a therapeutic effect.
- Take into account the increased risk of bleeding associated with SSRIs, particularly for older people or people taking other drugs that can damage the gastrointestinal mucosa or interfere with clotting (for example, NSAIDS or aspirin). Consider prescribing a gastroprotective drug in these circumstances.
- Monitor closely for suicidal ideation and behaviour during treatment with antidepressants and pregabalin.
- For people aged under 30 who are offered an SSRI or SNRI:¹
  - warn them that these drugs are associated with an increased risk of suicidal thinking and self-harm in a minority of people under 30
  - see them within 1 week of first prescribing
  - monitor the risk of suicidal thinking and self-harm weekly for the first month.
- If there is a risk of suicide consider the likelihood of toxicity in overdose, especially with venlafaxine.
- TCAs are also more dangerous in overdose than SSRIs.
- In older people, generally initiation and maintenance doses are lower than those used in younger adults and gradual and careful titration is required. Monitoring should be more frequent.
- For people who develop side effects soon after starting drug treatment, provide information and consider one of the following strategies:
  - monitoring the patient’s symptoms closely (if the side effects are mild and acceptable to the patient) or
  - reducing the dose of the drug or
  - stopping the drug and, according to the patient’s preference, offering either an alternative drug or a high-intensity psychological intervention.
- Stopping antidepressants abruptly can cause discontinuation/withdrawal symptoms. To minimise this risk when stopping antidepressants, the dose should be reduced gradually over an extended period of time.
- The MHRA has issued guidance regarding lower dose recommendations for citalopram and escitalopram due to the risk of dose-dependent QT interval prolongation⁴.
- Consider MHRA updated prescribing advice for venlafaxine⁵. Treatment with venlafaxine for severe depression or patients needing doses of 300mg daily or above should be initiated by specialist mental health practitioners; venlafaxine is contra-indicated in those with an identified high risk of a serious cardiac ventricular arrhythmia and uncontrolled hypertension. Regular blood pressure monitoring is recommended for all patients taking venlafaxine.
If, after consideration of the options, pharmacological treatment is the preferred option

**Consider:**
- Age
- Previous treatments
- Risks of deliberate self harm or accidental overdose
- Tolerability
- Patient preference
- Cost (if all else equal)

*Offer an SSRI, unless otherwise indicated. NICE CG113 2011 recommends sertraline as the most cost effective SSRI.*

Review efficacy and tolerability within two weeks of starting treatment and then every 2 to 4 weeks during the first three months and every 3 months thereafter.

Has there been any improvement after 12 weeks?

**YES**

Continue for at least six months at a therapeutic dose. NICE recommend at least 1 year. Monitor every two to three months. If appropriate to discontinue at this time do so gradually over at least four weeks.

**NO**

Reassess and consider another option. If a second pharmacological option is appropriate, another SSRI or an SNRI should be offered.

Review efficacy and tolerability within two weeks of starting treatment and then at 4, 6 and 12 weeks.

Has there been any improvement after 12 weeks?

**YES**

**NO**

Consider referral to secondary care specialist services.

Antipsychotics should not be prescribed in primary care for GAD.

*Discuss:
- Potential side effects including transient anxiety
- Delay in onset of effect
- Length of treatment
- Licence implications, paroxetine and escitalopram are licensed for GAD
- Potential for interactions.
- Potential discontinuation or withdrawal symptoms
- Provide written information
- Prescribe low initial doses and gradually increase.

If immediate symptomatic relief is required options to consider include:
- Benzodiazepines on a ‘when required’ basis for 2 to 4 weeks only (Refer to BNF)
- Sedative antihistamine e.g. hydroxyzine.
APPENDIX 2

Panic Disorder Treatment Algorithm

If, after consideration of the options, pharmacological treatment is the preferred option

*Discuss
- Potential side effects including transient anxiety
- Delay in onset of effect
- Length of treatment
- Potential discontinuation or withdrawal symptoms
- Provide written information
- Prescribe low initial dose and gradually increase.

Consider
- Age
- Previous treatments
- Risks of deliberate self harm or accidental overdose
- Tolerability
- Patient preference
- Cost (if all else equal)

*Offer an SSRI licensed for panic disorder e.g. citalopram, unless otherwise indicated

Review efficacy and tolerability within two weeks of starting treatment and then at 4, 6 and 12 weeks

Has there been any improvement after 12 weeks?

YES
- Continue for at least six months at a therapeutic dose. Monitor every two to three months. If appropriate to discontinue at this time do so gradually over at least four weeks. Long-term treatment may be necessary for some patients and should be offered if needed.

NO
- Consider referral to secondary care specialist services.

Issue Date: December 2013

Version 1.0

Review Date: December 2015
APPENDIX 3  Anxiety - Further Information

Generalised anxiety disorder (GAD) is a common disorder, of which the central feature is excessive worry, tension and feelings of apprehension about everyday events. Symptoms should be present on most days for at least 6 months for a diagnosis to be made and should cause clinically significant distress or impairment in social, occupational or other important areas of functioning.

A panic attack is a period in which there is a sudden onset of intense fear or apprehension with associated feelings of impending doom. Panic disorder is the presence of recurring, unforeseen panic attacks followed by at least 1 month of persistent worry about having another panic attack and concern about the consequences of a panic attack or a significant change in behaviour related to the attacks. At least two unexpected panic attacks are necessary for diagnosis. Panic disorder can be diagnosed with or without agoraphobia.

GAD and panic disorder vary in severity and complexity. It is important to consider symptom severity, duration, degree of distress, functional impairment, personal history and co-morbidities when undertaking a diagnostic assessment.

Anxiety symptoms include:

<table>
<thead>
<tr>
<th>Sensation of fear or dread</th>
<th>Irritability</th>
<th>Loss of concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>Loss of appetite</td>
<td>Insomnia</td>
</tr>
<tr>
<td>Memory loss</td>
<td>Dizziness</td>
<td>Back pain</td>
</tr>
<tr>
<td>Tremor</td>
<td>Tensing of muscles</td>
<td>Perspiration</td>
</tr>
<tr>
<td>Palpitations</td>
<td>Hypertension</td>
<td>Dyspnoea</td>
</tr>
<tr>
<td>Gastro-intestinal disturbances</td>
<td>Chest pain</td>
<td></td>
</tr>
</tbody>
</table>

Anxiety symptoms can be seen in depression with anxiety, psychotic illness and dementias; drug and alcohol withdrawal; some personality disorders; arrhythmias, thyrotoxicosis, hypoglycaemia and phaeochromocytoma.

Medication which can cause side effects that mimic symptoms of anxiety:

<table>
<thead>
<tr>
<th>Amphetamines</th>
<th>Antihypertensives (hydralazine, methyldopa)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticholinergics</td>
<td>Caffeine</td>
</tr>
<tr>
<td>Digoxin toxicity</td>
<td>Antipsychotics (akathisia)</td>
</tr>
<tr>
<td>Levodopa</td>
<td>Nicotine</td>
</tr>
<tr>
<td>Bronchodilators (salbutamol)</td>
<td></td>
</tr>
<tr>
<td>SSRIs</td>
<td></td>
</tr>
</tbody>
</table>

Issue Date: December 2013  Review Date: December 2015
Version 1.0
References

1. NICE CG 113 Generalized Anxiety Disorder and Panic Disorder, with or without Agoraphobia, in Adults; Management in Primary, Secondary and Community Care 2011 http://guidance.nice.org.uk/CG113

2. NICE CG 123 Common Mental Health Disorders (Identification and Pathways to Care) May 2011 http://guidance.nice.org.uk/CG123

